Celerion appoints vp of Global Bioanalytical Services

Will run bioanalytical operations in Zurich and Lincoln, Nebraska

Celerion, a US-based provider of early stage drug development solutions, has hired Raymond Farmen as vice president of Global Bioanalytical Services. He takes responsibility for bioanalytical operations in Zurich, Switzerland and Lincoln, Nebraska, US.

Farmen has more than 30 years of experience in the contract research organisation (CRO) and pharmaceutical industries. Prior to joining Celerion, he held executive positions at PharmOptima, a CRO specialising in ocular research services; Eurofins AvTech Laboratories, a small and large molecule bioanalytical chemistry specialist; and Camargo Pharmaceutical Services, which provides scientific and regulatory oversight during the drug development process.

You may also like

Media

Celerion earns five-year AAHRPP reaccreditation, reinforcing leadership in ethical clinical research

Celerion becomes the only US-headquartered CRO to hold the distinction, underscoring its long-standing commitment to participant safety and research integrity
Research & Development

Celerion receives a 2017 CRO leadership award in multiple categories for clinical research excellence

Celerion, a leading clinical research organisation, is pleased to announce it has received a CRO Leadership Award for the fourth time by global biopharmaceutical executives in Life Science Leader’s annual CRO Leadership Awards for 2017
Containment

Celerion adds Containment Room at Belfast facility

Will allow firm to carry out live biologics and vaccine studies
Research & Development

Celerion adds bronchoscopy suite in Belfast

Allows brochoalveolar lavage (BAL) to be performed using a multiplex approach
Research & Development

Celerion expands ADME suite in Lincoln, Nebraska

Now able to carry out on-site scintillation counting
Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Subscribe now